CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 7
Pages: 1  2  3  4  
Next
 

Anorexia/Cachexia in Patients with HIV: Lessons for the Oncologist

By Jamie H. Von Roenn, MD;Northwestern University,Chicago, Illinois
Kevin Knopf, MD;Evanston Hospital,Evanston, Illinois | July 1, 1996
Early intervention and attention to nutritional status are essential in patients with cachexia. Identification of reversible causes of decreased energy intake and/or weight loss is the first step in treatment. When such factors cannot be identified, pharmacologic interventions should be considered. To date, megestrol acetate is the most effective appetite stimulant. Appetite and weight gain occur to a greater and more rapid degree as megestrol dose increases. Unfortunately, the weight gain is due predominantly to an increase in fat mass. Whether this is due to a lack of exercise in the face of increased caloric intake and/or to the hypogonadal effects of megestrol acetate is being tested in ongoing clinical trials. Anabolic agents, particularly growth hormone, are exciting potential therapies. No data are yet available on alternate doses and schedules of growth hormone or on its effect in patients with decreased oral intake. Current studies addressing combination therapy with anabolic agents and appetite stimulants should clarify their respective therapeutic roles. [ONCOLOGY 10(7):1049-1056, 1996]

Introduction

Anorexia and cachexia are frequent complications of both HIV infection and cancer. Involuntary weight loss and associated malnutrition result in physical and psychological consequences that affect both morbidity and mortality. Numerous investigators have reported on the relationship between involuntary weight loss and adverse outcome in the setting of HIV infection or cancer. Malnutrition adversely affects immune function, increases the risk of infection, and diminishes tolerance to radiation therapy, response to chemotherapy, and overall survival [1].

Whether nutritional status is evaluated using simple clinical nutritional markers, such as serum albumin and percentage of usual body weight, or by sophisticated research techniques, the deleterious effects of malnutrition on the clinical course of HIV infection are well documented. Indeed, malnutrition is a predictor of both risk of hospitalization and survival [2]. Regardless of the clinical setting, death from wasting is directly related to the magnitude of tissue depletion, suggesting that the preservation and/or restoration of body cell mass may enhance survival [3].

Pathogenesis of Wasting

The pathogenesis of wasting is incompletely defined. However, it appears to result from complex interactions among decreased energy intake, altered energy expenditure, malabsorption, and hormonal/cytokine and metabolic abnormalities. The respective roles of individual factors, such as altered insulin sensitivity, hypertriglyceridemia, futile cycling of glucose and/or free fatty acids, hypermetabolism or hypometabolism, and alterations in the cytokine milieu, are difficult to identify. Ultimately, weight loss is determined by the balance between energy intake and energy expenditure. Increasingly, data suggest reduced energy intake as the major determinant of involuntary weight loss in patients with HIV infection, and, to a less degree, in those with cancer [1,4,5].

Anorexia is a frequent clinical complaint of patients with malignant disease or HIV infection. Bruera, in a review of 275 consecutive cancer patients admitted to a palliative care unit, noted anorexia to be present in 85% of patients, second in frequency only to the complaint of asthenia and more common than complaints of cancer-related pain [1].

Similarly, anorexia is a highly prevalent symptom in the setting of HIV infection, although its exact prevalence is unknown. In a review of clinical risk factors for malnutrition in 104 HIV-infected patients (including asymptomatic patients, as well as those with AIDS or AIDS-related complex [ARC]), anorexia was identified as the predominant risk factor in 60% of patients [6]. Furthermore, Burger et al reported the benefit of intensified oral nutritional intervention in malnourished HIV-infected outpatients, suggesting that poor spontaneous nutrient intake is an important pathogenetic factor in the development of HIV-related malnutrition [7].

In patients with HIV infection, the degree of weight loss has been closely associated with reduced energy intake. McCorkindale et al noted a correlation between weight loss and decreased oral intake over a 16-month period in asymptomatic patients with HIV infection or early ARC [8]. In an evaluation by Grunfeld et al comparing metabolic parameters and oral intake in HIV-seropositive subjects, seronegative controls, and AIDS patients with and without active secondary infections, a highly significant correlation between 28-day weight loss and caloric intake was identified, while no correlation was seen between resting energy expenditure and weight loss [5]. Similarly, Macallan et al found reduced energy intake, not elevated energy expenditure, to be the primary determinant of weight loss in 27 HIV-seropositive men at different stages of the disease [4].

Although weight loss appears to be progressive over the course of HIV infection, it does not occur continuously. Rather, weight is more often lost in a stepwise fashion in association with opportunistic complications of the underlying immunosuppression. This episodic weight loss is associated with decreased oral intake, which, during its early stages, may be amenable to therapeutic intervention.

Although not all investigators agree, a number of studies suggest that attention to oral intake by clinicians results in an improvement in overall nutritional status. McKinley et al demonstrated improved nutritional status in adult outpatients who received nutritional assessment, counseling, and follow-up, compared with outpatients who received no nutritional intervention [9]. In contrast, Chleblowski et al reported progressive weight loss in HIV-infected individuals despite dietary counseling, suggesting the need for earlier intervention and consideration of increased target levels for energy intake [10].

Etiology of Anorexia

The etiology of anorexia is incompletely understood.

Cytokine Production

The endogenous production of cytokines contributes to the development of anorexia and cachexia in both HIV infection and advanced cancer. Experimental therapy in vitro and in vivo with cytokines, such as interferon, tumor necrosis factor (TNF), and interleukin-1 (IL-1), can produce striking anorexia [11-13]. Tumor necrosis factor, although frequently cited as a major cause of anorexia, is not consistently elevated in the serum of patients with cancer cachexia or HIV-related wasting [11-14].

Although individual cytokines can result in significant anorexia when given as single factors in the experimental setting, tolerance to their anorexic effects generally develops and normal food intake resumes [11]. Synergism between cytokines (eg, IL-1 plus interferon-alfa or TNF) may result in irreversible anorexia, metabolic abnormalities, and progressive weight loss.

Reversible Causes

Food intake may be further decreased by readily identifiable, often reversible causes.

Nausea and Vomiting--Chronic nausea is a frequent complaint in patients with HIV infection or cancer. Nausea and vomiting can occur as a result of mechanical obstruction, infectious complications, or as a side effect of medications (see Tables 1 and 2).

In the setting of HIV infection, numerous medications are prescribed both for prophylaxis and treatment of opportunistic infections that, alone or in combination, may cause nausea and vomiting; examples include sulfamethoxazole(Drug information on sulfamethoxazole) for the treatment of Pneumocystis carinii pneumonia or clarithromycin(Drug information on clarithromycin) (Biaxin) as therapy or prophylaxis for Mycobacterium avium complex.

Nausea and vomiting occur as both an immediate and late effect of treatment with chemotherapeutic drugs such as cisplatin(Drug information on cisplatin) (Platinol). Radiation therapy, particularly when the treatment field includes the gastrointestinal tract, may also cause significant nausea.

In patients with advanced disease, whether cancer or HIV infection, a not infrequent cause of nausea and vomiting is a rapid increase in the dose of narcotic analgesics. In patients receiving high doses of narcotics, nausea may be severe, chronic, and accompanied by other gastrointestinal symptoms, including abdominal pain, constipation, and large bowel distention.

Psychosocial or Financial Factors--Decreased oral intake may result from psychosocial or financial factors. Patients have identified anxiety, depression, and/or a sense of isolation as factors interfering with oral intake. Neuropsychiatric symptoms associated with HIV infection and opportunistic pathogens of the central nervous system or central nervous system metastases, including dementia, sensory and motor abnormalities, and psychosis, also may result in decreased caloric intake.

Mechanical impediments to food intake secondary to strictures and/or progressive malignant disease further impair nutritional status. Oral and esophageal conditions that result in dysphasia and food aversions, such as esophageal candidiasis, aphthous stomatitis, and therapy-induced mucositis, occur in patients with both cancer and HIV infection. Cytomegaloviral or herpetic esophagitis are most frequently seen in the severely immunocompromised host. Bulky oropharyngeal Kaposi's sarcoma or other aerodigestive tract malignancies may also make eating painful or unpleasant.

Early satiety may further compromise oral intake. Early satiety may be secondary to ascites, hepatomegaly, or massive splenomegaly (due to progressive malignancy or organ infiltration by opportunistic infections [eg, cytomegalovirus or M avium complex]). Abdominal fullness, regardless of the cause, has been identified as one of the most important symptoms influencing weight loss in patients with unresectable malignancy [15].

Diarrhea is the most common gastrointestinal tract symptom in patients with HIV infection. It is often difficult to treat and may become a major debilitating aspect of a patient's illness. Not infrequently, diarrhea is associated with decreased oral intake, perhaps because patients attempt to reduce fecal output by restricting food intake, or because unabsorbed nutrients in the gastrointestinal tract suppress appetite. Similarly, diarrhea is a prominent symptom in patients with certain tumors, such as metastatic islet-cell cancers.

Pages: 1  2  3  4  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy